RxDoctor Payments Data

Steven Stowers, MD

Family Medicine · Montgomery, TXNPI 1891883609

Payments from drug & device makers

$15,588in general payments, 2019–2025

Across 982 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • GSK$925
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$15,570100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,588 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$157,370
Medicare patients
391
Services billed
10,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$98,612
TrulicityDulaglutide46$91,349
OzempicSemaglutide56$85,478
FarxigaDapagliflozin Propanediol32$36,816
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$35,653
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$24,300
ProliaDenosumab13$22,333
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$15,271
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$12,740
Tresiba Flextouch U-200Insulin Degludec14$11,780
BelsomraSuvorexant23$10,493
VascepaIcosapent Ethyl16$8,281
Rosuvastatin Calcium387$5,561
Atorvastatin Calcium513$5,033
SymbicortBudesonide/Formoterol Fumarate12$4,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,165$98,61284 claims
Lilly USA, LLCTrulicity$1,167$91,34946 claims
Novo NordiskOzempic$2,597$85,47856 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,593$66,08069 claims
GSKTrelegy Ellipta$925$35,65333 claims
AmgenProlia$493$22,33313 claims
MerckBelsomra$97$10,49323 claims
AbbVieSynthroid$717$3,73756 claims
PfizerPaxlovid$1,294$1,42917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Montgomery

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →